Tempus|HRD is launching this week in limited markets for all cancer types, with a broad launch slated for July. The test incorporates data from both the tumor and normal tissue to ensure that the HRD test accurately reflects a patient’s specific tumor makeup. Tempus|HRD does not require any additional tissue from the patient and features unique positivity thresholds for Ovarian Cancer, Breast Cancer, and Pancreatic Cancer, along with a general threshold for all other solid tumors. A patient’s HRD status has been shown to identify whether or not they are a good candidate for PARP inhibitors and platinum-based chemotherapy. It analyzes 18 of the commonly mutated genes in the HR pathway and calculates a genome-wide loss-of-heterozygosity (LOH) score to give clinicians a comprehensive view into a patient’s ability to repair cellular damage. Tempus|HRD is a DNA-based test, available as a supplementary option to xT, the company’s signature broad-panel genomic sequencing test that measures 648 genes, along with the full transcriptome. The Linkedin Influencer Marketing Bundle For Your Business But Under $100
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |